These are exciting times for biotech business Complement Therapeutics, which stands on the cusp of an important milestone in ...

Japanese MHLW grants orphan drug designation to Sanofi’s riliprubart for chronic inflammatory demyelinating polyneuropathy: Paris Tuesday, July 1, 2025, 09:00 Hrs [IST] The Mini ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...

As a result, complement activation initiated by CRP efficiently results in recruitment of the opsonic function of the system, but does not result in its proinflammatory and membrane-damaging effects.

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to Riliprubart for the investigational treatment of antibody-mediated rejection ...

The FDA has granted Orphan Drug designation to riliprubart for the investigational treatment of AMR in solid organ transplantation.

Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.

The complement system consists of a complex set of approximately 20 interacting proteolytic enzymes and regulatory proteins found in the plasma and body fluids. [6] Complement proteins are ...

Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved ...